Investigating a new type of drug that can inhibit the growth and survival of neuroblastoma and other childhood cancers
Professor Karim Malik and Dr Jodie Bojko are testing drugs that can prevent cancer cells from making growth-promoting proteins.
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Professor Karim Malik and Dr Jodie Bojko are testing drugs that can prevent cancer cells from making growth-promoting proteins.
Dr Daniel Williamson’s expert team will find the best malignant rhabdoid tumour models to test exciting new treatments.
Professor John Anderson’s team at University College London Great Ormond Street Institute of Child Health aim to revolutionise CAR T-cell therapy for solid tumours.
Dr Lizzie Tucker will assess a new type of treatment to fight ALK-driven childhood cancers like neuroblastoma.
Dr Jess Morgan at the University of York will review the latest experimental treatments for hard-to-treat neuroblastoma to help with decision-making.
Studying how neuroblastoma cells and immune cells interact over time to see how the cancer adapts to treatment.
Looking at what extra pieces of chromosomes do in neuroblastoma and how these work with the MYCN protein to convert healthy cells into cancer cells.
Modifying current immunotherapy so that it doesn't cause damage to nerve cells and instead targets three molecules to help kill neuroblastoma cells more effectively.
Finding out which changes to how DNA is read in neuroblastoma can give doctors more information about the cancer, and investigating whether these changes could be stopped through medicines.